Analysts, on average, had expected sales of $13.8 billion, according to Refinitiv data. Excluding items, Merck earned $1.40 per share, compared with estimates of $1.32 per share.
Keytruda sales rose 20% to $5.8 billion in the quarter, topping the estimates of $5.6 billion.
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-earnings-better-than-expected-keytruda-gardasil-strength-2023-04-27
Thursday, April 27, 2023
Merck beats first-quarter expectations
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.